Overview
- 16 inspections across 16 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-06-26.
At a glance
Inspections
16
Sites
16
Observations
0
Career since
Mar 2023
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Odin Pharmaceuticals, Inc. | 26 Jun 2026 | Human Drugs | |
| Charles River Laboratories, Inc. | 1 May 2026 | Human Drugs | |
| Rubicon Research Canada Limited | 24 Apr 2026 | Human Drugs | |
| Glogen Clinical Research Private Limited | 13 Feb 2026 | Human Drugs | |
| QPS Bioserve India Pvt. Limited | 6 Feb 2026 | Human Drugs |
Sites inspected
Odin Pharmaceuticals, Inc.Somerset, United States1 insp.
Charles River Laboratories, Inc.Saint-Laurent, Canada1 insp.
Rubicon Research Canada LimitedConcord, Canada1 insp.
Glogen Clinical Research Private LimitedHyderabad, India1 insp.
QPS Bioserve India Pvt. LimitedHyderabad, India1 insp.
Co-investigators
Investigators who share inspections with this person.
Melkamu Getie Kebtie2 shared
Vidhi J Jani1 shared
Lakecha N Lewis1 shared
Mayar M Mussa1 shared
Sheri L Stephenson1 shared
Angelica M Chica1 shared
Full investigator report
Get the verbatim findings behind Sarmistha Sanyal's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site